What cardiologists need to know about diabetes

Lancet

Volumn 350, Issue SUPPL.1, 1997, Pages 23-28

  Webster, Mark W I ^a   Scott, Russell S ^b  

^a GREEN LANE HOSPITAL   (New Zealand)

^b CHRISTCHURCH HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE;

ACUTE HEART INFARCTION; BLOOD CLOTTING DISORDER; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DYSLIPIDEMIA; GLUCOSE BLOOD LEVEL; HEART MUSCLE REVASCULARIZATION; HYPERGLYCEMIA; HYPERTENSION; KIDNEY DISEASE; PRIORITY JOURNAL; REVIEW;

EID: 0030790437     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0140-6736(97)90025-8     Document Type: Article

References (53)

1. Kannel WB. Lipids, diabetes and coronary heart disease: insights from the Framingham Study. Am Heart J 1985; 110: 1100-07.
2. Stamlcr J, Vaccaro O, Ncaton JD, Wcntworth D. Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16: 434-44.
3. Sowers JR, Epstein M. Diabetes mellitus and associated hypertension, vascular disease, and nephropathy. Hypertension 1995; 26: 869-79.
4. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-86.
5. The Diabetes Control and Complications Trial Research Group. Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. Am J Cardiol 1995; 75: 894-903.
6. Wang PH, Lau J, Chalmers TC. Meta-analysis of effects of intensive blood-glucose control on late complications of type I diabetes. Lancet 1993; 341: 1306-09.
7. Reichard P, Nilsson B, Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med 1993; 329: 304-09.
8. Barbosa J, Steffes MW, Sutherland DER, Connett JE, Rao KV, Mauer SM. Effect of glycemic control on early diabetic renal lesions. JAMA 1994; 272: 600-06.
9. Jensen-Urstad KJ, Reichard PG, Rosfors JS, Lindblad LEL, Jensen-Urstad MT. Early atherosclerosis is retarded by improved long-term blood glucose control in patients with IDDM. Diabetes 1996; 45: 1253-58.
10. Kuusisto J, Mykkanen L, Pyörälä K, Laakso M. NIDDM and its metabolic control predict coronary heart disease in the elderly subjects. Diabetes 1994; 43: 960-67.
11. Knatterud GL, Klimt CR, Levin ME, Jacobson ME, Goldner MG. Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. JAMA 1978; 240: 37-42.
12. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28: 103-17.
13. Malmberg K, Ryden L, Efendic S, et al. Randomized trial of insulinglucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI Study): effects on mortality at 1 year. J Am Coll Cardiol 1995; 26: 57-65.
14. University Group Diabetes Program. A study of the effects of hypoglycemic agents on vascular complications in patients with adultonset diabetes. Diabetes 1976; 25: 1129-53.
15. Garratt KN, Hassinger N, Grill DE, et al. Sulfonylurea drug use is associated with increased early mortality during direct coronary angioplasty for acute myocardial infarction among diabetic patients. J Am Coll Cardiol 1997; 29: 493A (abstr).
16. Koskinen P, Manttari M, Manninen V, Huttunen JK, Heinonen OP, Frick MH. Coronary heart disease incidence in NIDDM patients in the Helsinki heart study. Diabetes Care 1992; 15; 820-25.
17. Pyörälä K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgiersson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. Diabetes Care 1997; 20: 614-20.
18. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-09.
19. Lam KSL, Cheng IKP, Janus ED, Pang KWC. Cholesterol-lowering therapy may retard the progression of diabetic nephropathy. Diabetologia 1995; 38: 604-09.
20. Kasiske BL, Kalil RSN, Ma JZ, Liao M, Keane WF. Effect of antihypertensive therapy on the kidneys in patients with diabetes: a meta-regression analysis. Ann Intern Med 1993; 118: 129-38.
21. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456-62.
22. Kasiske BL, Ma JZ, Kalil RSN, Louis TA. Effects of antihypertensive therapy on serum lipids. Ann Intern Med 1995; 122: 133-41.
23. Grossman E, Messerli FH. Diabetic and hypertensive heart disease. Ann Intern Med 1996; 125: 304-10.
24. Ahtiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81-106.
25. ETDRS Investigators, Aspirin effects on mortality and morbidity in patients with diabetes mellitus. JAMA 1992; 268: 1292-300.
26. Davi G, Catalano I, Averna M, et al. Thromboxane biosynthesis and platelet function in type II diabetes mellitus. N Engl J Med 1990; 322: 1769-74.
27. ISIS-2 Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarctions: ISIS-2. Lancet 1988; ii: 349-60.
28. Litzelman DK, Slemenda CW, Langefeld CD, et al. Reduction of lower extremity clinical abnormalities in patients with non-insulin-dependent diabetes mellitus. Ann Intern Med 1993; 119: 36-41.
29. Woodfield SL, Lundergan CF, Reiner JS, et al. Angiographie findings and outcome in diabetic patients treated with thrombolytic therapy for acute myocardial infarction: the GUSTO-1 experience. J Am Coll Cardiol 1996; 28: 1661-69.
30. Fibrinolytic Therapy Trialists' Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994; 343: 311-22.
31. Malmberg K for the DIGAMI Study Group. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. BMJ 1997; 314: 1512-15.
32. Nattrass M. Managing diabetes after myocardial infarction. BMJ 1997; 314: 1497.
33. Kendall MJ, Lynch KP, Hjalmarson A, Kjekshus J. Beta-blockers and sudden cardiac death. Ann Intern Med 1995; 123: 358-67.
34. Jonas M, Reicher-Reiss H, Boyko V, et al. Usefulness of beta-blocker therapy in patients with non-insulin-dependent diabetes mellitus and coronary artery disease. Am J Cardiol 1996; 77: 1273-77.
35. Mangano DT, Layug EL, Wallace A,Tateo I. Effect of atenolol on mortality and cardiovascular morbidity after noncadiac surgery, N Engl J Med 1996; 335: 1713-20.
36. Lager I, Smith U, Blohme G, Effect of cardioselective and non-selective beta-blockade on hypoglycaemic response in insulin-dependent diabetes. Lancet 1979; i: 458-62.
37. Braun S, Boyko V, Behar S, et al. Calcium antagonists and mortality in patients with coronary artery disease: a cohort study of 11,575 patients. J Am Coll Cardiol 1996; 28: 7-11.
38. McVeigh G, Brennan G, Hayes R, Johnston D. Primary nitrate tolerance in diabetes mellitus. Diabetologia 1994; 37: 115-17.
39. Zarich S, Waxman S, Freeman RT, Mittleman M, Hegarty P, Nesto RW. Effect of autonomic nervous system dysfunction on the circadian pattern of myocardial ischaemia in diabetes mellitus. J Am Coll Cardiol 1994; 24: 956-62.
40. Langer A, Freeman MR, Josse RG, Armstrong PW. Metaiodobenzylguanidine imaging in diabetes mellitus: assessment of cardiac sympathetic denervation and its relation to autonomie dysfunction and silent myocardial ischaemia. J Am Coll Cardiol 1995; 25: 610-18.
41. Marchant B, Umachandran V, Stevenson R, Kopelman PG, Timmis AD. Silent myocardial ischaemia: role of subclinical neuropathy in patients with and without diabetes. J Am Coll Cardiol 1993; 22: 1433-37.
42. Ewing DJ, Boland O, Neilson JM, Cho CG, Clarke BF. Autonomic neuropathy, QT interval lengthening, and unexpected deaths in male diabetic patients. Diabetologia 1991; 34: 182-85.
43. Wei K, Dorian P, Newman D, Langer A. Association between QT dispersion and autonomic dysfunction in patients with diabetes mellitus. J Am Coll Cardiol 1995; 26: 859 63
44. Sandrone G, Mortara A, Torzilln D, La Rovere MT, Malnant G. Lombardi F. Effects of beta blockers (atenolol or metoprolol) on heart rate variability after acute myocardial infarction. Am J Cardiol 1994 74: 340-45.
45. Barzilay JI, Kronmal RA, Bittner V, Eaker E, Evans C, Foster ED. Coronary artery disease and coronary artery bypass grafting in diabetic patients aged ≥65 years (report from the Coronary Artery Surgery Study [CASS] registry). Am J Cardiol 1994; 74: 334-39.
46. Accola KD, Jones EL, Craver JM, Weintraub WS, Guyton RA. Bilateral mammary artery grafting; avoidance of complications with extended use. Ann Thorac Surg 1993; 56: 872-78.
47. Morris JJ, Smith LR, Jones RH, et al. Influence of diabetes and mammary artery grafting on survival after coronary bypass. Circulation 1991; 84 (suppl): III275-84.
48. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. N Engl J Med 1996; 335: 217-25.
49. Stein B, Weintraub WS, Gebhart SP, et al. Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty. Circulation 1995; 91: 979-89.
50. Kornowski R, Mintz GS, Kent KM, et al. Increased restenosis in diabetes mellitus after coronary interventions is due to exaggerated intimal hyperplasia. Circulation 1997; 95: 1366-69.
51. Aronson D, Bloomgarden Z, Rayfield EJ. Potential mechanisms promoting restenosis in diabetic patients. J Am Coll Cardiol 1996; 27: 528-35.
52. Shindler DM, Kostis JB, Yusuf S, et al. Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) trials and registry. Am J Cardiol 1996; 77: 1017-20.
53. Moye LA, Pfeffer MA, Wun CC, et al. Uniformity of captopril benefit in the SAVE study: subgroup analysis. Eur Heart J 1994; 15 (suppl B): 2-8.